Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 6 · inside the Ichimoku cloud · RSI 41 · MACD below its signal
None of the 29 investors followed here reported a position in HELP.NE in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a HELP.NE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Glavine (Paul)Director of Issuer | — | 248K | — |
| Sep 29, 2026 | So (Eric How-Lun)Director of Issuer | — | 248K | — |
| Sep 28, 2026 | Cavers (Greg)Senior Officer of Issuer | Acquisition in the public market at price 12.91 per share. | 3K | $38.73K |
| Sep 20, 2026 | Halstead (Michael I.)Senior Officer of Issuer | Acquisition in the public market at price 13.47 per share. | 100K | $1.35M |
| Sep 14, 2026 | Fahel (Gabriel)Senior Officer of Issuer | Acquisition in the public market at price 13.11 per share. | 2K | $26.23K |
| Sep 14, 2026 | Fahel (Gabriel)Senior Officer of Issuer | Acquisition in the public market at price 13.12 per share. | 1K | $13.12K |
| Sep 13, 2026 | Halstead (Michael I.)Senior Officer of Issuer | — | 68.6K | — |
| Sep 7, 2026 | Glavine (Paul)Director of Issuer | Acquisition in the public market at price 12.47 per share. | 100K | $1.25M |
| Sep 7, 2026 | Glavine (Paul)Director of Issuer | — | 230.9K | — |
| Sep 7, 2026 | Glavine (Paul)Director of Issuer | — | 230.9K | — |
| Sep 7, 2026 | So (Eric How-Lun)Director of Issuer | Acquisition in the public market at price 12.39 per share. | 100K | $1.24M |
| Sep 3, 2026 | So (Eric How-Lun)Director of Issuer | Acquisition in the public market at price 12.09 per share. | 100K | $1.21M |
| Sep 2, 2026 | Fahel (Gabriel)Senior Officer of Issuer | Disposition in the public market at price 11.76 per share. | 27.5K | $323.48K |
| Sep 2, 2026 | Glavine (Paul)Director of Issuer | Acquisition in the public market at price 11.78 per share. | 100K | $1.18M |
| Sep 1, 2026 | Bartlone (Aaron Frank)Senior Officer of Issuer | Disposition in the public market at price 11.82 per share. | 30.8K | $364.35K |
| Sep 1, 2026 | Cavers (Greg)Senior Officer of Issuer | Disposition in the public market at price 11.82 per share. | 39.2K | $462.79K |
| Sep 1, 2026 | Firestone (Theresa)Director of Issuer | Disposition in the public market at price 11.82 per share. | 16.4K | $194.27K |
| Sep 1, 2026 | Tziras (George)Senior Officer of Issuer | Exercise of rights at price 11.75 per share. | 979 | $11.50K |
| Aug 31, 2026 | Bartlone (Aaron Frank)Senior Officer of Issuer | — | 83.3K | — |
| Aug 31, 2026 | Cavers (Greg)Senior Officer of Issuer | — | 78.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.5 | 11.0 | -33.1 | 7.1 | -12.8 | 48.7 | 17.8 | 48.7 | 7.6 | -14.4 | +35.6% | ||
| 2025 | 12.6 | -17.5 | -22.6 | 1.0 | 18.3 | 4.5 | -7.0 | -2.6 | -20.6 | 24.2 | -14.4 | 27.6 | −12.5% |
| 2024 | -5.7 | -7.0 | 16.1 | -12.0 | -2.1 | -20.4 | 6.8 | -17.7 | -2.8 | 16.5 | 5.4 | -13.8 | −36.9% |
| 2023 | 20.5 | 42.0 | -25.4 | -20.8 | -14.3 | 38.9 | -2.0 | -16.3 | 74.4 | 27.3 | -31.9 | -14.5 | +27.7% |
| 2022 | -14.7 | -11.7 | -9.7 | -27.5 | 16.2 | -16.3 | 5.6 | 93.4 | -54.4 | -9.0 | -19.7 | -15.3 | −72.3% |
| 2021 | 10.1 | -23.1 | -15.6 | 64.4 | -23.0 | 48.5 | 51.2 | -8.9 | -20.6 | -18.3 | -17.2 | -20.2 | −20.6% |
| 2020 | 112.4 | +112.4% |
No analyst coverage for this instrument.
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
No recent headlines.